Cerus makes the INTERCEPT Blood System, which is used to reduce pathogens in donated blood components for transfusion. It last closed at $1.85 on Nov 20, down 2.63% on the day. The next earnings report for CERS is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, CERS reported EPS of $0.00 on revenue of $57.7M, with revenue up 9.5% from a year ago. Over its last 8 reports the stock moved an average of 14.0% the session after earnings. Over the last 12 months CERS insiders bought $0 of stock on the open market and sold $3.1M, according to SEC Form 4 filings.
AI Auto Pilots
Is CERS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CERS.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on CERSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
CERS · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 15% below its 20 day and 24% below its 50 day average. It is 31% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the swing low (Nov 16) at $1.83, and the nearest resistance the Pivot at $1.87.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.1%/day
Key levels
$3.4752 week high+87.6%
$2.54100 day average+37.3%
$2.42200 day average+30.8%
$2.3050 day average+24.3%
$2.16Swing high (Nov 11)+16.8%
$2.1320 day average+15.1%
$1.93Pivot R1+4.3%
$1.87Pivot+1.1%
$1.85Last close
$1.83Swing low (Nov 16)−1.1%
$1.80Pivot S1−2.7%
$1.4752 week low−20.5%
Indicators
RSI (14)
36.12
Weak, oversold below 30
Neutral
MACD
-0.13
Below its signal line
Bearish
Stochastic
9.7
Near the bottom of its range
Oversold
ADX (14)
26.4
Trending down
Williams %R
-95.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-94.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−8.4%
Change over 10 sessions
Bearish
ATR (14)
$0.15
Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Turning down
Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityNormal, 17.9%/day
Key levels
$3.4752 week high+87.6%
$2.54100 day average+37.3%
$2.42200 day average+30.8%
$2.3050 day average+24.3%
$2.16Swing high (Nov 11)+16.8%
$2.1320 day average+15.1%
$1.93Pivot R1+4.3%
$1.87Pivot+1.1%
$1.85Last close
$1.83Swing low (Nov 16)−1.1%
$1.80Pivot S1−2.7%
$1.4752 week low−20.5%
Indicators
RSI (14)
38.50
Weak, oversold below 30
Neutral
MACD
-0.12
Below its signal line
Bearish
Stochastic
3.3
Near the bottom of its range
Oversold
ADX (14)
16.7
No clear trend
Williams %R
-97.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-142.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−25.7%
Change over 10 sessions
Bearish
ATR (14)
$0.33
Typical daily range, 17.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CERS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CERS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow CERS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for CERSHow many large options trades hit CERS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in CERS in the last 90 days.
From SEC Form 4 filings by CERS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CERS is in one of them and how their past CERS trades turned out.
Cerus is a biomedical products company based in Concord, California. Its main product is the INTERCEPT Blood System, which is designed to reduce bloodborne pathogens in donated blood components intended for transfusion. The system is used to treat platelets and plasma, and a related version produces a fibrinogen complex for treating bleeding linked to fibrinogen deficiency. Cerus sells these products through its own sales force and distributors in several countries, while its red blood cell system remains in development.